File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies

TitleOne-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies
Authors
Issue Date2002
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2002, v. 16 n. 4, p. 793-798 How to Cite?
AbstractAim: To test the efficacy of omeprazole, furazolidone and amoxicillin triple therapy for the treatment of Helicobacter pylori infection after failure of standard firstline therapy recommended by the Asia-Pacific Consensus on the management of H. pylori infection. Methods: Patients with failed H. pylori eradication received omeprazole, 20 mg, furazolidone, 100 mg, and amoxicillin, 1 g, all twice daily for 1 week. Endoscopy (CLO test, histology and culture) was performed before treatment. Post-treatment H. pylori status was determined by 13C-urea breath test 6 weeks later. Results: Fifty patients were recruited. Resistance to metronidazole, clarithromycin and both drugs was in the range of 50-64%, 60-75% and 40-50%, respectively, after failure of first-line therapy. Amoxicillin resistance was not found. The intention-to-treat and per protocol H. pylori eradication rates were 52% and 53%, respectively. Patients with double resistance to metronidazole and clarithromycin showed the lowest eradication rate (38%), which was significantly lower than that of patients with sensitive strains (88%). Side-effects were minimal and compliance was excellent (98%). Conclusions: One-week omeprazole, furazolidone and amoxicillin rescue therapy achieved a high eradication rate in strains sensitive to metronidazole and clarithromycin. This is a cheap and safe rescue regimen when guided by pre-treatment sensitivity testing.
Persistent Identifierhttp://hdl.handle.net/10722/78267
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, WMen_HK
dc.contributor.authorWong, BCYen_HK
dc.contributor.authorLu, Hen_HK
dc.contributor.authorGu, Qen_HK
dc.contributor.authorYin, Yen_HK
dc.contributor.authorWang, WHen_HK
dc.contributor.authorFung, FMYen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorXia, HHXen_HK
dc.contributor.authorXiao, SDen_HK
dc.contributor.authorLam, SKen_HK
dc.date.accessioned2010-09-06T07:40:59Z-
dc.date.available2010-09-06T07:40:59Z-
dc.date.issued2002en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2002, v. 16 n. 4, p. 793-798en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78267-
dc.description.abstractAim: To test the efficacy of omeprazole, furazolidone and amoxicillin triple therapy for the treatment of Helicobacter pylori infection after failure of standard firstline therapy recommended by the Asia-Pacific Consensus on the management of H. pylori infection. Methods: Patients with failed H. pylori eradication received omeprazole, 20 mg, furazolidone, 100 mg, and amoxicillin, 1 g, all twice daily for 1 week. Endoscopy (CLO test, histology and culture) was performed before treatment. Post-treatment H. pylori status was determined by 13C-urea breath test 6 weeks later. Results: Fifty patients were recruited. Resistance to metronidazole, clarithromycin and both drugs was in the range of 50-64%, 60-75% and 40-50%, respectively, after failure of first-line therapy. Amoxicillin resistance was not found. The intention-to-treat and per protocol H. pylori eradication rates were 52% and 53%, respectively. Patients with double resistance to metronidazole and clarithromycin showed the lowest eradication rate (38%), which was significantly lower than that of patients with sensitive strains (88%). Side-effects were minimal and compliance was excellent (98%). Conclusions: One-week omeprazole, furazolidone and amoxicillin rescue therapy achieved a high eradication rate in strains sensitive to metronidazole and clarithromycin. This is a cheap and safe rescue regimen when guided by pre-treatment sensitivity testing.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.en_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAmoxicillin - administration & dosage - therapeutic useen_HK
dc.subject.meshAnti-Infective Agents, Local - administration & dosage - therapeutic useen_HK
dc.subject.meshAnti-Ulcer Agents - administration & dosage - therapeutic useen_HK
dc.subject.meshDrug Resistance, Multiple, Bacterialen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFurazolidone - administration & dosage - therapeutic useen_HK
dc.subject.meshHelicobacter Infections - diagnosis - drug therapy - microbiologyen_HK
dc.subject.meshHelicobacter pylori - drug effectsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMicrobial Sensitivity Testsen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOmeprazole - administration & dosage - therapeutic useen_HK
dc.subject.meshPilot Projectsen_HK
dc.subject.meshTreatment Failureen_HK
dc.titleOne-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapiesen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0269-2813&volume=16&issue=4&spage=793&epage=798&date=2002&atitle=One-week+omeprazole,+furazolidone+and+amoxicillin+rescue+therapy+after+failure+of+Helicobacter+pylori+eradication+with+standard+triple+therapiesen_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1365-2036.2002.01223.xen_HK
dc.identifier.pmid11929398-
dc.identifier.scopuseid_2-s2.0-0036113541en_HK
dc.identifier.hkuros72103en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036113541&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume16en_HK
dc.identifier.issue4en_HK
dc.identifier.spage793en_HK
dc.identifier.epage798en_HK
dc.identifier.isiWOS:000175115300017-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.scopusauthoridLu, H=26642892200en_HK
dc.identifier.scopusauthoridGu, Q=24469982400en_HK
dc.identifier.scopusauthoridYin, Y=36847525300en_HK
dc.identifier.scopusauthoridWang, WH=23390847100en_HK
dc.identifier.scopusauthoridFung, FMY=7003833944en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridXia, HHX=8757161400en_HK
dc.identifier.scopusauthoridXiao, SD=12780231400en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats